Microbot Medical Inc. (NASDAQ: MBOT)

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000883975
Market Cap 60.70 Mn
P/B 0.78
P/E -4.64
P/S 0.00
ROIC (Qtr) -25.60
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 899,000.00
Debt/Equity (Qtr) 0.01

About

Microbot Medical Inc., also known as MBOT, operates in the medical device industry with a focus on next-generation robotic endoluminal surgery devices. The company's primary operations involve the research, design, and development of innovative medical technologies, specifically targeted at the minimally invasive surgery space. With its headquarters in Israel, Microbot Medical serves both local and international markets. The company generates revenue through the development and commercialization of its products, including the LIBERTY Endovascular...

Read more

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 6.76M provide 22.75x coverage of short-term debt 297000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 81.76M provides 90.95x coverage of total debt 899000, indicating robust asset backing and low credit risk.
  • Short-term investments of 73.45M provide solid 34.52x coverage of other current liabilities 2.13M, indicating strong liquidity.
  • Tangible assets of 81.76M provide robust 38.42x coverage of other current liabilities 2.13M, indicating strong asset backing.
  • Short-term investments of 73.45M provide 247.32x coverage of short-term debt 297000, showing strong liquidity management.

Bear case

  • Operating cash flow of (10.98M) barely covers its investment activities of (69.36M), with a coverage ratio of 0.16, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (69.36M) provide weak support for R&D spending of 6.72M, which is -10.31x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Short-term investments of 73.45M significantly exceed cash reserves of 6.76M, which is 10.87x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
  • The company's operating cash flow of (10.98M) shows concerning coverage of stock compensation expenses of 1.10M, with a -9.95 ratio indicating potential earnings quality issues.
  • Free cash flow of (11.02M) provides weak coverage of capital expenditures of 42000, with a -262.40 ratio suggesting additional external financing needs for growth initiatives.

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 209.14 Bn 76.14 21.76 0.00 Bn
2 BDX Becton Dickinson & Co 58.36 Bn 34.78 2.67 19.18 Bn
3 ALC Alcon Inc 39.57 Bn 37.80 3.89 5.24 Bn
4 RMD Resmed Inc 37.01 Bn 25.74 7.04 0.85 Bn
5 WST West Pharmaceutical Services Inc 19.95 Bn 40.58 6.61 0.30 Bn
6 HOLX Hologic Inc 16.94 Bn 29.95 4.13 2.52 Bn
7 COO Cooper Companies, Inc. 16.64 Bn 44.39 4.07 2.51 Bn
8 SOLV Solventum Corp 15.00 Bn 9.84 1.79 5.14 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.69 3.14
EV to Cash from Ops. EV/CFO -5.17 37.60
EV to Debt EV to Debt 63.09 23.10
EV to EBIT EV/EBIT -4.34 50.25
EV to EBITDA EV/EBITDA -4.06 19.58
EV to Free Cash Flow [EV/FCF] EV/FCF -5.15 -19.40
EV to Market Cap EV to Market Cap 0.93 -1.68
EV to Revenue EV/Rev 0.00 171.31
Price to Book Value [P/B] P/B 0.78 6.03
Price to Earnings [P/E] P/E -4.64 204.20
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -1.11
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.52
Dividend per Basic Share Div per Share (Qtr) 0.00 0.25
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 8.75
Interest Coverage Int. cover (Qtr) 0.00 -119.10
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -180.00 -55.01
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 1,182.35 200.65
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -1.49
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -16.64 -56.39
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -37.45 -106.80
EBIT Growth (1y) % EBIT 1y % (Qtr) -16.64 -36.51
EBT Growth (1y) % EBT 1y % (Qtr) -16.64 -47.44
EPS Growth (1y) % EPS 1y % (Qtr) 43.75 -15.70
FCF Growth (1y) % FCF 1y % (Qtr) -22.84 59.41
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 0.00 68.22
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.54
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.03
Cash Ratio Cash Ratio (Qtr) 2.30 2.49
Current Ratio Curr Ratio (Qtr) 27.53 7.77
Debt to Equity Ratio Debt/Equity (Qtr) 0.01 0.55
Interest Cover Ratio Int Coverage (Qtr) 0.00 -119.10
Times Interest Earned Times Interest Earned (Qtr) 0.00 -119.10
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 0.00 -2,368.64
EBIT Margin % EBIT Margin % (Qtr) 0.00 -2,472.65
EBT Margin % EBT Margin % (Qtr) 0.00 -2,442.59
Gross Margin % Gross Margin % (Qtr) 0.00 30.07
Net Profit Margin % Net Margin % (Qtr) 0.00 -2,438.52